Boehringer Ingelheim has inaugurated its Large Scale Cell Culture (LSCC) biopharmaceutical plant at Vienna, Austria. Built over a period of six years at a cost of more...

ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating...

ISPE and its members are developing the roadmap to introduce Industry 4.0, also called the Smart Factory, at the pharmaceutical industry as Pharma 4.0 – an operating...

Finnish nanoparticle medicine specialist Nanoform and German drugmaker Boehringer Ingelheim have agreed to collaborate on proof-of-concept studies related to Nanoform’s...

German drugmaker Boehringer Ingelheim and UK biotech Enara Bio have agreed to collaborate on the research and development of novel targeted cancer immunotherapies...

German privately owned drugmaker Böhringer Ingelheim has reached an agreement in principle to settle nearly 3,000 US lawsuits alleging that its Pradaxa (dabigatran...

Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma...